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Abstract
Objectives—To evaluate FCGR3B copy number variation (CNV) in African and European
populations and to determine if FCGR3B copy number is associated with SLE and SLE nephritis
risk in Afro-Caribbeans, adjusting for African genetic ancestry.
Methods—We estimated FCGR3B to determine if there were ethnic variations in CNV
(unrelated unadmixed Europeans and Africans). We then examined CNV at FCGR3B in relation
to SLE and SLE nephritis within a case–control collection of 134 cases of SLE (37 with SLE
nephritis) and 589 population controls of mainly Afro-Caribbean descent resident in Trinidad.
Results—We found a significant difference in copy number FCGR3B distribution between
unadmixed African and European UK cohorts, with 27 (29%) vs 3 (5%) for those with low (0 or
1) copy FCGR3B, respectively, P = 0.002. In a Trinidadian SLE case–control study, low FCGR3B
CNV was associated with SLE risk 1.7 (95% CI 1.1, 2.8), P = 0.02, which remained after
adjustment for African genetic ancestry; odds ratios (ORs) 1.7 (95% CI 1.0, 2.8), P = 0.04.
Conclusion—Our studies suggest that FCGR3B low copy number is associated with SLE risk in
Afro-Caribbean populations independently of CNV due to African ancestry.
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Introduction
Emerging analyses of copy number variation (CNV) across the genome has highlighted the
role that structural variation may play in the aetiology of genetic disease susceptibility. CNV
has been reported in a number of recent studies [1], with increasing reports of individual
gene CNV and association of CNV with specific diseases [2–13], including an association
between low FCGR3B CNV and systemic immunity in a number of European cohorts [14–
16] and C4 gene deletions and SLE risk [13]. There is also evidence for regional CNV
variation between different ethnic groups [1]. However, association of low FCGR3B CNV
was not confirmed in a Chinese lupus nephritis cohort of 202 individuals, compared with
146 controls [17]. Further studies on Columbian patients of Spanish (Paisa) origin have
confirmed association of low and high FCGR3B CNV in 146 subjects with SLE, and
identified possible epistasis with CCL3L1 (CC chemokine ligand 3-like 1) [18], which is
encoded by a variable copy number gene that may additionally enhance inflammatory
responses and increase the chance of autoimmune disease [10].
SLE and SLE nephritis show large ethnic differences in disease risk, with prevalence rates
6–8 times higher in African-Americans and in Caribbean migrants of West African descent
than in Europeans, but little is known about FCGR3B CNV in ethnically diverse African
cohorts with SLE. We decided to investigate the association of low CNV in unadmixed
Africans and Europeans, and subsequently in a case–control study of SLE within a
Trinidadian Afro-Caribbean population.
Methods
CNV was measured in this study by paralogue ratio test (PRT) assay as previously described
and validated [19]. First, we established FCGR3B CNV in a population-based control
sample of unrelated unadmixed Europeans and Africans from the UK with no known renal
disease. Individuals were selected via primary care clinics if they claimed all four
grandparents were of either European or African descent. Additionally, data were validated
from data collected on country of origin and mother’s main language. Finally, these
individuals were genotyped using independent genome-wide ancestry informative markers
(AIMs) as described previously [20], five-way admixture estimated using ADMIXMAP
software (admixture mapping software; open source software developed at London School
of Hygiene & Tropical Medicine) and those included with >97.5% African ancestry. All
study participants gave written informed consent. The study was approved by London
School of Hygiene & Tropical Medicine ethics board and the Trinidad and Tobago Ministry
of Health.
We then examined CNV at FCGR3B (as described earlier by PRT methods) in relation to
SLE and SLE nephritis within a case–control collection of 134 cases of SLE (37 with SLE
nephritis) and 589 population controls of mainly Afro-Caribbean descent resident in
Trinidad [21]. Novel aspects of this study included the use of five-way admixture in this
population to examine separately the effects of admixture on SLE and CNV. Analysis of
admixture was based on a panel of AIMs chosen to have large allele frequency differentials
between West African, European, Chinese, Indian and Native American populations. A
Bayesian model for population admixture, individual admixture and locus ancestry was
fitted by Markov chain simulation [20].
All analyses were carried out using Stata statistical software (release 10.0, 2008; Stata
Corporation, College Station, TX, USA), and adjusted for five-way admixture, age and
gender. The association between the relevant outcome and CNV status at time of survey was
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explored using logistic regression analysis–effects on risk being estimated by odds ratios
(ORs) with 95% CIs.
Results
We were able to obtain FCGR3B CNV results on ~96% of the samples using the PRT assay,
which comprised: (i) UK unadmixed European and African control cohort; (ii) SLE Afro-
Caribbean Trinidad cohort; and (iii) non-SLE Afro-Caribbean Trinidad controls.
FCGR3B
In the West African unadmixed control population, 27/93 (29%) also had significantly
higher proportions of low (0, 1) FCGR3B CNV compared with European control 3/56 (5%)
populations, with P = 0.002. Similar results were found for low FCGR3B in a Trinidadian
Afro-Caribbean control population, P < 0.05 compared with European controls. Prevalence
of FCGR3B CNV in European controls was similar when validated with results from a
secondary European cohort (MRC 1946 European cohort). In Fig. 1, One Trinidadian Afro-
Caribbean control (0 cases), two African controls living in the UK and no Europeans had
zero copies of FCGR3B. Numbers of low FCGR3B CNV were significantly higher in SLE
cases compared with Afro-Caribbean controls, P = 0.01. The Afro-Caribbean control with
zero FCGR3B CNV had no evidence of other autoimmune disease or high ANA status
identified from medical records. Trinidadian Afro-Caribbean SLE cases had significantly
higher proportions of low (0, 1) FCGR3B CNV [32/126 (25%)] compared with non-SLE
Afro-Caribbean control [79/479 (16%)] populations, with P = 0.01.
Table 1 shows summary characteristics across three groups of Afro-Caribbean patients in
Trinidad: (i) Afro-Caribbean non-SLE controls; (ii) Afro-Caribbean SLE cases; and (iii)
Afro-Caribbean SLE nephritis cases. Estimation of African (P = 0.0004) and European
ancestry (P = 0.002) significantly differed between SLE cases and non-SLE controls.
Estimates of Chinese (P = 0.0001) and Native American ancestry (P = 0.02) were
significantly higher in SLE cases than in non-SLE controls. Of those with low FCGR3B
CNV with genetic estimates of ancestry (admixture), SLE cases did not have significantly
lower mean African ancestry than non-SLE controls (67 vs 68%, respectively), P = 0.7.
Table 2 shows the association of low (0 or 1) CNV at FCGR3B with SLE from a case–
control study of SLE and SLE nephritis in Trinidad Afro-Caribbeans. The crude OR
adjusted for age group and gender was 1.7 (95% CI 1.1, 2.8), P = 0.02. The OR for low
FCGR3B CNV associated with SLE risk remained similar after adjustment for five-way
ancestry including African admixture; OR 1.7 (95% CI 1.0, 2.8), P = 0.04. For SLE
nephritis, the crude OR for low FCGR3B adjusted for age group and gender was 2.3 (95%
CI 1.1, 4.8), and adjusted for five-way ancestry including African admixture OR was 2.4
(95% CI 1.1, 5.5), P = 0.03.
We confirmed that the association with low CNV was independent of five-way admixture
for SLE and SLE nephritis. There was no additional risk for SLE nephritis compared with
SLE patients without nephritis in either the adjusted or unadjusted models. ANA status was
strongly associated with SLE diagnosis but was not associated with African admixture.
Discussion
The most significant results are the distributions of FCGR3B number between African and
European populations. This is statistically significant and present in several populations of
West African descent (West Africans in the UK, and Trinidadian Afro-Caribbeans).
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This study suggests an association of low FCGR3B CNV with SLE and SLE nephritis in an
Afro-Caribbean cohort, independent of ethnic background and is the first study to include
five-way admixture. Calculations based on the actual numbers genotyped indicate our study
was 80% powered to detect ORs of 1.7 and 2.4, respectively, for association of FCGR3B
with SLE and lupus nephritis. Recent studies have identified that FCGR3B may be involved
in immune complex clearance, as low FCGR3B is associated with SLE [12, 14, 15].
Willcocks et al. [12] showed that both in a family with Fc gamma RIIIb deficiency and in
the normal population, FCGR3B CNV correlates with protein expression, with neutrophil
uptake of and adherence to immune complexes, and with soluble serum Fc gamma RIIIb.
The authors suggested that reduced Fc gamma RIIIb expression may contribute to the
impaired clearance of immune complexes, a recognized feature of SLE, which may support
the association between low FCGR3B CNV and SLE found in European (and other)
populations [12]. Further recent studies have identified association between high and low
FCGR3B CNV with SLE (and primary SS) in a Spanish Paisa Columbian population, stated
as 85% European and 15% Amerindian with possible epistatic interactions in those SLE
individuals with two copies of CCL3L1, although no formal adjustment for admixture was
undertaken [18]. No association of FCGR3B was found with SLE nephritis in 202 Chinese
individuals lupus nephritis cohort [17].
Further examination showed FCGR3B was not in linkage disequilibrium (LD) with any of
the AIMs selected to estimate admixture. Although Afro-Caribbeans are at substantially
higher risk of SLE and SLE nephritis, the risk of low FCGR3B CNV with SLE remains after
adjusting for African ancestry. As in previous studies, there was no additional risk for low
CNV with organ-specific immunity such as SLE nephritis, within SLE cases. Further studies
will determine if the effect of FCGR3B CNV is associated with SLE risk in other ethnic
groups.
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Rheumatology key messages
• Our studies suggest FCGR3B low copy number is associated with SLE risk in
Afro-Caribbean populations independently of CNV due to African ancestry.
• We found significant differences in distribution of FCGR3B CNV between
African and European populations.
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Fig. 1.
Distribution of FCGR3B by PRT CNV in West African (unadmixed), Afro-Caribbean and
European populations. Totals (N): Trinidadian Afro-Caribbean SLE cases (n = 126);
Trinidadian Afro-Caribbean non-SLE controls (n = 479); West Africans (n = 93); and
Europeans (n = 56).
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Table 1
SLE and SLE nephritis in relation to FCGR3B copy number and African ancestry: characteristics at survey of
participants
Risk factor
Afro-Caribbean
controls, n (%)
n = 589
Afro-Caribbean
SLE cases,
n (%)
n = 134
Afro-Caribbean
SLE nephritis subset of
SLE cases, n (%)
n = 37
P-value
All SLE cases vs
non-SLE controls
Age at survey, yearsa 0.2
 15–24 16 (3) 1 (1) 0 (0)
 25–34 76 (13) 17 (13) 7 (19)
 35–44 163 (28) 43 (32) 12 (32)
 45–54 148 (25) 43 (32) 12 (32)
 55–64 117 (20) 20 (15) 3 (8)
 >65 64 (11) 10 (7) 3 (8)
Education after 18 years NA 25 (19) 7 (19)
Lack of running water at 12 years NA 50 (37) 15 (41)
Genetic ancestry
Mean (SD)
n = 558 (five-way
admixture)
n = 119 (five-way
admixture)
n = 32 (five-way
admixture)
African 0.68 (0.17) 0.62 (0.24) 0.61 (0.26) 0.0004
European 0.12 (0.11) 0.10 (0.07) 0.09 (0.07) 0.002
Native American 0.05 (0.05) 0.07 (0.05) 0.07 (0.06) 0.02
Indian 0.08 (0.08) 0.09 (0.07) 0.09 (0.08) 0.12
Chinese 0.08 (0.07) 0.12 (0.12) 0.14 (0.14) 0.0001
Proportions of African ancestry
per copy category n = 450 n = 113 n = 31
0, 1 copies FCGR3B 75 (17) 28 (25) 10 (32)
 Mean African ancestry (S.D.), % 0.68 (0.18) 0.67 (0.25) 0.69 (0.21) 0.7
2 copies FCGR3B 342 (76) 70 (62) 19 (61)
 Mean African ancestry (S.D.), % 0.69 (0.18) 0.59 (0.25) 0.54 (0.29) 0.001
≥3 copies FCGR3B 33 (7) 15 (13) 2 (6)
 Mean African ancestry (S.D.), % 0.65 (0.22) 0.65 (0.21) 0.85 (0.02) 1.0
a
Five missing age data. N/A: not available.
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Table 2
Adjusted regression models for SLE and SLE nephritis risk with FCGR3B; controlling for African genetic
ancestry
SLE cases vs
non-SLE controls
SLE nephritis vs
non-SLE controls
SLE nephritis vs
non-renal SLE
n = 562
(prevalence %),
P-value
Adjusted ORa
(95% CI)
genotypic
n = 480,
P-value
Adjusted ORa
(95% CI)
genotypic
n = 113,
P-value
Adjusted
ORa (95% CI)
genotypic
≥2 copies FCGR3B 1.0 (95% CI) 1.0 (95% CI) 1.0 (95% CI)
0, 1 copies FCGR3B 0.04 1.7 (1.0, 2.8) 0.03 2.4 (1.1, 5.5) 0.3 1.7 (0.7, 4.5)
aOR adjusted for age, gender and African genetic ancestry.
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